In-utero exposure to nelfinavir-ethyl methyl sulfone

AIDS. 2016 Nov 13;30(17):2729-2730. doi: 10.1097/QAD.0000000000001254.

Abstract

Ethyl methyl sulfone contained in nelfinavir between 2007 and 2008 accidentally exposed embryos and fetuses to a powerful mutagen. We report data for 101 HIV-uninfected children exposed in utero included in the French prospective national cohort. The incidence of malformation was similar to that in the cohort as a whole with different drug exposures; no children had developed cancer after 9 years of follow-up.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Congenital Abnormalities / epidemiology*
  • Drug Contamination
  • Ethyl Methanesulfonate / administration & dosage
  • Ethyl Methanesulfonate / adverse effects
  • Ethyl Methanesulfonate / analogs & derivatives*
  • Female
  • Follow-Up Studies
  • France / epidemiology
  • HIV Protease Inhibitors / administration & dosage*
  • HIV Protease Inhibitors / chemistry
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Maternal-Fetal Exchange*
  • Mutagens / administration & dosage
  • Mutagens / adverse effects*
  • Nelfinavir / administration & dosage*
  • Nelfinavir / chemistry
  • Pregnancy
  • Prenatal Exposure Delayed Effects / epidemiology*
  • Prospective Studies

Substances

  • HIV Protease Inhibitors
  • Mutagens
  • ethyl methylaminosulfonate
  • Ethyl Methanesulfonate
  • Nelfinavir